Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|August 1, 2017
- Pharmaceutical Executive-08-01-2017
- Volume 37
- Issue 8
Pharmaceutical Executive, August 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 9 years ago
Health Policy Problem Solver: Fumie Griegoabout 9 years ago
Dealmaking in 2017: Striking a Balanceabout 9 years ago
Beyond the Science: Commercial Implications From ASCO 2017about 9 years ago
News Spotlight: Pharmaabout 9 years ago
Pharma’s Marijuana Makeoverabout 9 years ago
The 'Hear' and Now for Pharma and Social Mediaabout 9 years ago
Pressure Mounts on FDA, Pharma to Tackle Opioid Abuseabout 9 years ago
Syncing Social Media With Value-Care Modelabout 9 years ago
AI-based Social Listening as Aid to Pharmacovigilanceabout 9 years ago
Country Report: IndonesiaAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5